Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH
New NASH survey available on NASHTRUTH.com reveals that 6 out of 10 NASH patients say there is not enough information about the disease available to them
NASHTRUTH.com provides people living with NASH with resources to start a more productive dialogue with their healthcare providers about their disease
NASHTRUTH.com features information about the risks of disease progression, key findings from a recent NASH disease state survey that has identified critical gaps in knowledge about the disease and personal stories from people living with NASH. The site also contains resources to help people living with NASH have more productive conversations with their doctors. Among the tools and information available are a downloadable discussion guide and links to patient organizations that provide additional support and resources.
“The first time I heard the word ‘NASH’ was the same day I was diagnosed with liver cirrhosis,” said
The NASH survey, which polled patients with fibrosis due to NASH, healthcare providers and the general public, uncovered an urgent need for better information about NASH and the risks associated with disease progression. While almost all patients surveyed (89%) conducted their own research upon learning of their diagnosis, the majority reported being dissatisfied with the quantity and quality of NASH information available to them. The survey also found that patients are much more likely to say there is not enough information regarding NASH (61%) compared to other conditions like obesity (30%) and type 2 diabetes (17%). Moreover, among those patients who have researched the condition, more than half (54%) rated the quality of available information about NASH as fair or poor.
The survey also revealed that patients are not always aware of the serious consequences of NASH, despite the fact that a majority of healthcare providers believe that all or most patients understand disease progression. Among patients surveyed, 43% reported that they do not recall learning about the risk of progressing to cirrhosis at diagnosis. However, 70% of patients said they would be much more motivated to make lifestyle changes if they knew they were at high risk of developing liver cirrhosis.
“The NASH survey results provide important insights into the community’s understanding of this disease,” said
The NASH disease state survey was conducted by
About Advanced Liver Fibrosis due to NASH
Nonalcoholic steatohepatitis (NASH) is a serious progressive liver disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in progressive fibrosis (scarring) that can lead to cirrhosis, eventual liver failure, cancer and death. Advanced fibrosis is associated with a substantially higher risk of liver-related morbidity and mortality in patients with NASH, and as early as 2020, the disease is projected to become the leading cause of liver transplants in the United States. There are currently no medications approved for the treatment of NASH.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
For more information about Intercept, please contact:
Source: Intercept Pharmaceuticals, Inc.